跳至主要内容
临床试验/NCT04798976
NCT04798976Unknown不适用

Personalized Evidence-based Treatment Improves Survival in Patients With Invasive Breast Cancer

Center of Personalized Medicine, Pirogova1 个研究点 分布在 1 个国家目标入组 3,000 人开始时间: 2021年3月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
3,000
试验地点
1
主要终点
The percentage of guideline-consistent and personalized EBM recommendations

研究概览

简要总结

A population-based case-cohort study of breast cancer-specific survival among all first invasive breast cancer cases

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
— 至 70 Years(Child, Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • All women with stage I-III disease who survived at least 12 months post-diagnosis

排除标准

  • Unknown cause of death Treatment outside the region (thus precluding the treatment assessment)

研究组 & 干预措施

CDSS (MedicBK) Analysis

干预措施: neoadjuvant/adjuvant therapy (Drug)

Core Laboratory Analysis

干预措施: neoadjuvant/adjuvant therapy (Drug)

结局指标

主要结局

The percentage of guideline-consistent and personalized EBM recommendations

时间窗: 3-year

The percentage of guideline-consistent and personalized EBM recommendations acted on by clinicians in patients with first invasive breast cancer. All discrepancies between routine and CDSS-recommended treatment resulting in frame of guideline-consistent therapy and personalized EBM therapy will be adjudicated by core laboratory.

次要结局

  • Breast cancer-specific survival(3-year)
  • Quantify the performance of the CDSS (MedicBK) algorithm(3-year)
  • Predictors(3-year)

研究者

发起方
Center of Personalized Medicine, Pirogova
申办方类型
Other
责任方
Principal Investigator
主要研究者

Evgeny Pokushalov

Director for research and development

Center of Personalized Medicine, Pirogova

研究点 (1)

Loading locations...

相似试验